Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"

Gynecologic Oncology

Volumn 136, Issue 2, 2015, Pages 224-229

  Solheim, O ^a   Trope C G ^a,b   Rokkones, E ^a   Kaern J ^a   Paulsen, T ^a   Salvesen, H B ^c   Hagen, B ^d   Vereide, A B ^e   Fossa S D ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Cisplatin based chemotherapy; Fertility; Ovarian germ cell cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; MUELLERIAN INHIBITING FACTOR; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; DYSGERMINOMA; FEMALE; FEMALE FERTILITY; GERM CELL TUMOR; GONAD DYSFUNCTION; GONAD FUNCTION; HEALTH CARE SURVEY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT OVARIAN GERM CELL TUMOR; MALIGNANT TERATOMA; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OUTPATIENT; OVARY FUNCTION; OVARY TUMOR; PREGNANCY; PRIORITY JOURNAL; QUESTIONNAIRE; SALPINGOOOPHORECTOMY; SELF REPORT; DRUG EFFECTS; FERTILITY; GONAD; MORTALITY; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS;

ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; FERTILITY; GONADS; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; SURVEYS AND QUESTIONNAIRES;

EID: 84923083464     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.12.010     Document Type: Article

References (25)

1. H.O. Smith, M. Berwick, C.F. Verschraegen, et al. Incidence and survival rates for female malignant germ cell tumors Obstet Gynecol 107 2006 1075 1085
2. R.S. Aurora, R.D. Alston, T.O. Eden, M. Geraci, and J.M. Birch Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003 Cancer 118 2012 4290 4297
3. M.E. Fallat, and J. Hutter Preservation of fertility in pediatric and adolescent patients with cancer Pediatrics 121 5 2008 e1461 e1469
4. Berek JS, Hacker NF. Nonepithelial ovarian and fallopian tube cancers. In: Barek JS, Hacker NF, editors. Practical gynecologic oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 511-41.
5. N. Murugaesu, P. Schmid, G. Dancey, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment J Clin Oncol 24 2006 4862 4866
6. D.M. Gershenson Management of ovarian germ cell tumors J Clin Oncol 25 2007 2938 2943
7. O. Solheim, J. Kærn, C.G. Tropé, et al. Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009) Gynecol Oncol 131 11 2013 330 335
8. D. Matei, J. Brown, and L. Frazier Updates in the management of ovarian germ cell tumors Am Soc Clin Oncol Educ Book 2013 2013 210 216
9. C. Parkinson, H. Hatcher, and H. Earl Multidisciplinary management of malignant ovarian germ cell tumors Gynecol Oncol 121 2011 625 636
10. R.I. Schilsky, B.J. Lewis, R.J. Sherins, and R.C. Young Gonadal dysfunction in patients receiving chemotherapy for cancer Ann Intern Med 93 1 1980 Jul 109 114
11. S.J. Lee, L.R. Schover, A.H. Partridge, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients J Clin Oncol 24 2006 2917 2931
12. J. Pont, and W. Albrect Fertility after chemotherapy for testicular germ cell cancer Fertil Steril 68 1997 1 5
13. C. Bokemeyer, C.C. Berger, M.A. Kuczyk, et al., Evaluation of long-term toxicity after chemotherapy for testicular cancer J Clin Oncol 14 1996 2923 2932
14. D.M. Gershenson Menstrual and reproductive function after treatment with combination therapy for malignant ovarian germ cell tumors J Clin Oncol 6 1988 270 275
15. D.M. Gershenson, A.M. Miller, and V.L. Champion et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study J Clin Oncol 19 2007 2792 2797
16. J.J. Low, A. Ilancheran, and J.S. Ng Malignant ovarian germ-cell tumors Best Pract Res Clin Obstet Gynaecol 26 3 2012 347 355
17. J.J. Low, L.C. Perrin, A.J. Crandon, and N.F. Hacker Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases Cancer 89 2000 391 398
18. C.P. Hagen, L. Aksglaede, K. Sorensen, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients J Clin Endocrinol Metab 11 2010 5003 5010
19. I.A. van Rooij, F.J.M. Broekmans, G.J. Scheffer, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study Fertil Steril 4 2005 979 987
20. S.L. Fong, J.S.E. Laven, F.G.A. Hakvoort-Cammel, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone Hum Reprod 4 2009 982 990
21. R.D. van Beek, M. van den Heuvel-Eibrink, J.S.E. Laven, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood J Clin Endocrinol Metab 10 2007 3869 3874
22. G. Zanetta, C. Bonazzi, M.G. Cantu, et al. Survival and reproductive function after treatment of malignant ovarian germ cell tumors J Clin Oncol 19 2001 1015 1020
23. Er befolknings fruktbarhet endret? Tidsskr Nor Laegeforen 128 2008 330 333
24. J. Gaffan, L. Holden, E.S. Newlands, et al. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumors - a retrospective long-term follow-up study Br J Cancer 89 2003 49 54
25. I. Demeestre, P. Brice, Peccatori, et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial J Clin Oncol 31 2013 903 909